ABSTRACT The coronavirus disease 2019 (COVID-19) pandemic is a challenge for ongoing efforts to combat antimicrobial-resistant (AMR) bacterial infections. As we learn more about COVID-19 disease and drug stewardship evolves, there is likely to be a lasting impact of increased use of antimicrobial agents and antibiotics, as well as a lack of consistent access to health care across many populations. Sexually transmitted infections have been underreported during the pandemic and are often caused by some of the most drug-resistant pathogens. In their recent article in mBio , Parzych et al. (E. M. Parzych, S. Gulati, B. Zheng, M. A. Bah, et al., mBio 12:e00242-21, 2021, https://doi.org/10.1128/mBio.00242-21 ) focus on protection against Neisseria gonorrhoeae infection via in vivo delivery of an antigonococcal DNA-encoded antibody that has been modified for increased complement activation. Nucleic acid approaches are highly adaptable and could be tremendously beneficial for personalized strategies to combat AMR pathogens.
【저자키워드】 antimicrobial resistance, Personalized medicine, Bacteria, AMR, DNA-encoded antibodies, gene-encoded antibodies, 【초록키워드】 COVID-19, coronavirus disease, pandemic, antibody, Infection, Antibiotics, complement, COVID-19 disease, Health, Neisseria gonorrhoeae, Pathogens, in vivo, Bacterial infections, Care, sexually transmitted infection, Activation, effort, approach, populations, antimicrobial agent, lack, caused, drug-resistant, 【제목키워드】 COVID-19, antimicrobial, resistance, shadow,